About Us

Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
My Watchlist
Indicators
Local Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Instil Bio, Inc. (NQ:TIL)

7.000 -0.130 (-1.82%)
Streaming Delayed Price Updated: 11:57 AM EST, Jan 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Instil Bio, Inc.

< Previous 1 2 3 4 5 Next >
On Thursday, there are stocks with unusual volume. Let's take a look. ↗
Via Chartmill
Unusual volume stocks in Wednesday's session ↗
Via Chartmill
News headline image
Instil Bio Announces ImmuneOnco’s Presentation of ‘2510 Monotherapy Data in Patients with 2L+ Squamous NSCLC at the 2025 World Conference on Lung Cancer (WCLC)
From Instil Bio
Via GlobeNewswire
News headline image
Instil Bio Posts Wider Loss in Q2 ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Instil Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update
From Instil Bio
Via GlobeNewswire
News headline image
ImmuneOnco Announced Preliminary Safety & Efficacy Data from the Clinical Trial Studying IMM2510/AXN-2510, a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in Front-line NSCLC in China
From Instil Bio
Via GlobeNewswire
News headline image
Here are the top movers in Monday's session. ↗
Let's have a look at what is happening on the US markets in the middle of the day on Monday. Below you can find the top gainers and losers in today's session. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Instil Bio Announces U.S. F.D.A. Clearance of Investigational New Drug (IND) Application for AXN-2510, a PD-L1xVEGF Bispecific Antibody, for a Phase 1 Trial in Relapsed/Refractory Solid Tumors
From Instil Bio
Via GlobeNewswire
News headline image
Instil Bio Names John Maraganore, Ph.D., to Board Role Supporting the Advancement of PD-L1xVEGF Bispecific Antibody Program
From Instil Bio
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
These stocks are moving in today's after hours session ↗
Discover the top movers in Monday's after-hours session and stay informed about the post-market dynamics. 
Via Chartmill
News headline image
These stocks that are showing activity before the opening bell on Monday. ↗
Let's have a look at what is happening on the US markets before the opening bell on Monday. Below you can find the top gainers and losers in today's pre-market session. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Instil Bio Announces Appointment of Jamie Freedman, M.D., Ph.D., as Chief Medical Officer
From Instil Bio
Via GlobeNewswire
News headline image
Instil Bio to Participate in the 2025 Jefferies Global Healthcare Conference
From Instil Bio
Via GlobeNewswire
News headline image
Instil Bio and ImmuneOnco to Host Investor and Analyst Breakfast to Discuss the Evolving PD-(L)1xVEGF Bispecific Antibody Landscape and Clinical Trial Updates During the 2025 ASCO Annual Meeting in Chicago
From Instil Bio
Via GlobeNewswire
News headline image
Keep an eye on the top gainers and losers in Thursday's session. ↗
Stay up-to-date with the latest market trends one hour before the close of the markets on Thursday. Explore the top gainers and losers during today's session in our detailed report. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
These stocks are moving in today's session ↗
Keep an eye on the top gainers and losers in Thursday's session, as they reflect the most notable price movements. 
Via Chartmill
News headline image
Instil Bio and ImmuneOnco Announced the Phase 2 Trial in First-line NSCLC of IMM2510/AXN-2510 (‘2510), a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in China is on Track to Complete Enrollment in Q3 2025; Initial Results Anticipated
From Instil Bio
Via GlobeNewswire
News headline image
What's going on in today's pre-market session ↗
Wondering what's happening in Tuesday's pre-market session? Find an overview in this article. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Pegasystems Shares Are Trading Higher By Over 6%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Instil Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update
From Instil Bio
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
Instil Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
From Instil Bio
Via GlobeNewswire
News headline image
Instil Bio Announces Clinical Progress in China for IMM2510/SYN-2510, a Clinical-Stage PD-L1xVEGF Bispecific Antibody
From Instil Bio
Via GlobeNewswire
News headline image
Bullish Outlook On Instil Bio's Investigational Cancer Drug: Jefferies Sees Over 300% Stock Upside ↗
Jefferies upgrades Instil Bio to "Buy" with a $52 target, anticipating significant growth for PD-(L)1xVEGF class and SYN2510's potential in cancer treatments. 
Via Benzinga
News headline image
Instil Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update
From Instil Bio
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.